Venus Remedies Limited (VENUSREM.NS) Stock Competitors & Peer Comparison
See (VENUSREM.NS) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| VENUSREM.NS | ₹1,633.50 | +4.99% | 21.8B | 21.24 | ₹76.91 | N/A |
| SUNPHARMA.BO | ₹1,783.55 | +0.24% | 4.3T | 39.20 | ₹45.50 | +0.93% |
| SUNPHARMA.NS | ₹1,782.20 | +0.12% | 4.3T | 37.22 | ₹47.88 | +0.93% |
| DIVISLAB.BO | ₹6,623.50 | +0.44% | 1.8T | 68.55 | ₹96.62 | +0.45% |
| DIVISLAB.NS | ₹6,623.00 | +0.40% | 1.8T | 68.50 | ₹96.69 | +0.45% |
| TORNTPHARM.NS | ₹4,420.90 | +1.87% | 1.5T | 69.29 | ₹63.80 | +0.34% |
| TORNTPHARM.BO | ₹4,418.70 | +1.87% | 1.5T | 69.86 | ₹63.25 | +0.34% |
| ZYDUSLIFE.NS | ₹1,089.00 | +0.41% | 1.1T | 21.75 | ₹50.06 | +1.01% |
| ZYDUSLIFE.BO | ₹1,088.90 | +0.32% | 1.1T | 21.76 | ₹50.05 | +1.01% |
| DRREDDY.NS | ₹1,278.20 | +0.84% | 1.1T | 24.84 | ₹51.46 | +0.63% |
Stock Comparison
VENUSREM.NS vs SUNPHARMA.BO Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, SUNPHARMA.BO has a market cap of 4.3T. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while SUNPHARMA.BO trades at ₹1,783.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas SUNPHARMA.BO's P/E ratio is 39.20. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to SUNPHARMA.BO's ROE of +0.15%. Regarding short-term risk, VENUSREM.NS is more volatile compared to SUNPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check SUNPHARMA.BO's competition here
VENUSREM.NS vs SUNPHARMA.NS Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, SUNPHARMA.NS has a market cap of 4.3T. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while SUNPHARMA.NS trades at ₹1,782.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas SUNPHARMA.NS's P/E ratio is 37.22. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to SUNPHARMA.NS's ROE of +0.15%. Regarding short-term risk, VENUSREM.NS is more volatile compared to SUNPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check SUNPHARMA.NS's competition here
VENUSREM.NS vs DIVISLAB.BO Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, DIVISLAB.BO has a market cap of 1.8T. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while DIVISLAB.BO trades at ₹6,623.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas DIVISLAB.BO's P/E ratio is 68.55. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to DIVISLAB.BO's ROE of +0.17%. Regarding short-term risk, VENUSREM.NS is more volatile compared to DIVISLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check DIVISLAB.BO's competition here
VENUSREM.NS vs DIVISLAB.NS Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, DIVISLAB.NS has a market cap of 1.8T. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while DIVISLAB.NS trades at ₹6,623.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas DIVISLAB.NS's P/E ratio is 68.50. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to DIVISLAB.NS's ROE of +0.17%. Regarding short-term risk, VENUSREM.NS is more volatile compared to DIVISLAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check DIVISLAB.NS's competition here
VENUSREM.NS vs TORNTPHARM.NS Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, TORNTPHARM.NS has a market cap of 1.5T. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while TORNTPHARM.NS trades at ₹4,420.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas TORNTPHARM.NS's P/E ratio is 69.29. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to TORNTPHARM.NS's ROE of +0.27%. Regarding short-term risk, VENUSREM.NS is more volatile compared to TORNTPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check TORNTPHARM.NS's competition here
VENUSREM.NS vs TORNTPHARM.BO Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, TORNTPHARM.BO has a market cap of 1.5T. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while TORNTPHARM.BO trades at ₹4,418.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas TORNTPHARM.BO's P/E ratio is 69.86. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to TORNTPHARM.BO's ROE of +0.27%. Regarding short-term risk, VENUSREM.NS is more volatile compared to TORNTPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check TORNTPHARM.BO's competition here
VENUSREM.NS vs ZYDUSLIFE.NS Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, ZYDUSLIFE.NS has a market cap of 1.1T. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while ZYDUSLIFE.NS trades at ₹1,089.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas ZYDUSLIFE.NS's P/E ratio is 21.75. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to ZYDUSLIFE.NS's ROE of +0.20%. Regarding short-term risk, VENUSREM.NS is more volatile compared to ZYDUSLIFE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check ZYDUSLIFE.NS's competition here
VENUSREM.NS vs ZYDUSLIFE.BO Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, ZYDUSLIFE.BO has a market cap of 1.1T. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while ZYDUSLIFE.BO trades at ₹1,088.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas ZYDUSLIFE.BO's P/E ratio is 21.76. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to ZYDUSLIFE.BO's ROE of +0.20%. Regarding short-term risk, VENUSREM.NS is more volatile compared to ZYDUSLIFE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check ZYDUSLIFE.BO's competition here
VENUSREM.NS vs DRREDDY.NS Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, DRREDDY.NS has a market cap of 1.1T. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while DRREDDY.NS trades at ₹1,278.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas DRREDDY.NS's P/E ratio is 24.84. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to DRREDDY.NS's ROE of +0.12%. Regarding short-term risk, VENUSREM.NS is more volatile compared to DRREDDY.NS. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check DRREDDY.NS's competition here
VENUSREM.NS vs DRREDDY.BO Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, DRREDDY.BO has a market cap of 1.1T. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while DRREDDY.BO trades at ₹1,277.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas DRREDDY.BO's P/E ratio is 18.84. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to DRREDDY.BO's ROE of +0.12%. Regarding short-term risk, VENUSREM.NS is more volatile compared to DRREDDY.BO. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check DRREDDY.BO's competition here
VENUSREM.NS vs LUPIN.NS Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, LUPIN.NS has a market cap of 1T. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while LUPIN.NS trades at ₹2,267.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas LUPIN.NS's P/E ratio is 19.46. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to LUPIN.NS's ROE of +0.28%. Regarding short-term risk, VENUSREM.NS is more volatile compared to LUPIN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check LUPIN.NS's competition here
VENUSREM.NS vs LUPIN.BO Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, LUPIN.BO has a market cap of 1T. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while LUPIN.BO trades at ₹2,268.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas LUPIN.BO's P/E ratio is 24.03. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to LUPIN.BO's ROE of +0.28%. Regarding short-term risk, VENUSREM.NS is more volatile compared to LUPIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check LUPIN.BO's competition here
VENUSREM.NS vs MANKIND.BO Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, MANKIND.BO has a market cap of 964.9B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while MANKIND.BO trades at ₹2,336.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas MANKIND.BO's P/E ratio is 50.54. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to MANKIND.BO's ROE of +0.13%. Regarding short-term risk, VENUSREM.NS is more volatile compared to MANKIND.BO. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check MANKIND.BO's competition here
VENUSREM.NS vs MANKIND.NS Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, MANKIND.NS has a market cap of 964.6B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while MANKIND.NS trades at ₹2,336.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas MANKIND.NS's P/E ratio is 50.40. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to MANKIND.NS's ROE of +0.13%. Regarding short-term risk, VENUSREM.NS is more volatile compared to MANKIND.NS. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check MANKIND.NS's competition here
VENUSREM.NS vs AUROPHARMA.BO Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, AUROPHARMA.BO has a market cap of 849.5B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while AUROPHARMA.BO trades at ₹1,462.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas AUROPHARMA.BO's P/E ratio is 24.84. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to AUROPHARMA.BO's ROE of +0.10%. Regarding short-term risk, VENUSREM.NS is more volatile compared to AUROPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check AUROPHARMA.BO's competition here
VENUSREM.NS vs AUROPHARMA.NS Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, AUROPHARMA.NS has a market cap of 841.4B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while AUROPHARMA.NS trades at ₹1,462.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas AUROPHARMA.NS's P/E ratio is 24.25. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to AUROPHARMA.NS's ROE of +0.10%. Regarding short-term risk, VENUSREM.NS is more volatile compared to AUROPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check AUROPHARMA.NS's competition here
VENUSREM.NS vs LAURUSLABS.BO Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, LAURUSLABS.BO has a market cap of 781.2B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while LAURUSLABS.BO trades at ₹1,447.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas LAURUSLABS.BO's P/E ratio is 90.55. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to LAURUSLABS.BO's ROE of +0.19%. Regarding short-term risk, VENUSREM.NS is more volatile compared to LAURUSLABS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check LAURUSLABS.BO's competition here
VENUSREM.NS vs LAURUSLABS.NS Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, LAURUSLABS.NS has a market cap of 781.1B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while LAURUSLABS.NS trades at ₹1,446.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas LAURUSLABS.NS's P/E ratio is 92.62. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to LAURUSLABS.NS's ROE of +0.19%. Regarding short-term risk, VENUSREM.NS is more volatile compared to LAURUSLABS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check LAURUSLABS.NS's competition here
VENUSREM.NS vs ALKEM.NS Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, ALKEM.NS has a market cap of 627.9B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while ALKEM.NS trades at ₹5,251.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas ALKEM.NS's P/E ratio is 27.27. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to ALKEM.NS's ROE of +0.18%. Regarding short-term risk, VENUSREM.NS is more volatile compared to ALKEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check ALKEM.NS's competition here
VENUSREM.NS vs ALKEM.BO Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, ALKEM.BO has a market cap of 627.9B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while ALKEM.BO trades at ₹5,251.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas ALKEM.BO's P/E ratio is 27.27. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to ALKEM.BO's ROE of +0.18%. Regarding short-term risk, VENUSREM.NS is more volatile compared to ALKEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check ALKEM.BO's competition here
VENUSREM.NS vs GLENMARK.NS Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, GLENMARK.NS has a market cap of 611.3B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while GLENMARK.NS trades at ₹2,166.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas GLENMARK.NS's P/E ratio is 44.95. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to GLENMARK.NS's ROE of +0.14%. Regarding short-term risk, VENUSREM.NS is more volatile compared to GLENMARK.NS. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check GLENMARK.NS's competition here
VENUSREM.NS vs GLENMARK.BO Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, GLENMARK.BO has a market cap of 611.1B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while GLENMARK.BO trades at ₹2,165.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas GLENMARK.BO's P/E ratio is 44.92. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to GLENMARK.BO's ROE of +0.14%. Regarding short-term risk, VENUSREM.NS is more volatile compared to GLENMARK.BO. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check GLENMARK.BO's competition here
VENUSREM.NS vs IPCALAB.BO Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, IPCALAB.BO has a market cap of 416.8B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while IPCALAB.BO trades at ₹1,643.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas IPCALAB.BO's P/E ratio is 36.58. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to IPCALAB.BO's ROE of +0.15%. Regarding short-term risk, VENUSREM.NS is more volatile compared to IPCALAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check IPCALAB.BO's competition here
VENUSREM.NS vs IPCALAB.NS Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, IPCALAB.NS has a market cap of 416.6B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while IPCALAB.NS trades at ₹1,641.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas IPCALAB.NS's P/E ratio is 36.54. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to IPCALAB.NS's ROE of +0.15%. Regarding short-term risk, VENUSREM.NS is more volatile compared to IPCALAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check IPCALAB.NS's competition here
VENUSREM.NS vs SUVENPHAR.NS Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, SUVENPHAR.NS has a market cap of 412.4B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while SUVENPHAR.NS trades at ₹1,078.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas SUVENPHAR.NS's P/E ratio is 98.90. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to SUVENPHAR.NS's ROE of +0.09%. Regarding short-term risk, VENUSREM.NS is more volatile compared to SUVENPHAR.NS. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check SUVENPHAR.NS's competition here
VENUSREM.NS vs SUVENPHAR.BO Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, SUVENPHAR.BO has a market cap of 411.4B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while SUVENPHAR.BO trades at ₹1,075.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas SUVENPHAR.BO's P/E ratio is 98.29. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to SUVENPHAR.BO's ROE of +0.07%. Regarding short-term risk, VENUSREM.NS is more volatile compared to SUVENPHAR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check SUVENPHAR.BO's competition here
VENUSREM.NS vs AJANTPHARM.BO Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, AJANTPHARM.BO has a market cap of 372B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while AJANTPHARM.BO trades at ₹2,977.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas AJANTPHARM.BO's P/E ratio is 36.71. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to AJANTPHARM.BO's ROE of +0.26%. Regarding short-term risk, VENUSREM.NS is more volatile compared to AJANTPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check AJANTPHARM.BO's competition here
VENUSREM.NS vs AJANTPHARM.NS Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, AJANTPHARM.NS has a market cap of 371.9B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while AJANTPHARM.NS trades at ₹2,976.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas AJANTPHARM.NS's P/E ratio is 35.18. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to AJANTPHARM.NS's ROE of +0.26%. Regarding short-term risk, VENUSREM.NS is more volatile compared to AJANTPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check AJANTPHARM.NS's competition here
VENUSREM.NS vs JBCHEPHARM.BO Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, JBCHEPHARM.BO has a market cap of 348.3B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while JBCHEPHARM.BO trades at ₹2,169.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas JBCHEPHARM.BO's P/E ratio is 48.75. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to JBCHEPHARM.BO's ROE of +0.19%. Regarding short-term risk, VENUSREM.NS is more volatile compared to JBCHEPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check JBCHEPHARM.BO's competition here
VENUSREM.NS vs JBCHEPHARM.NS Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, JBCHEPHARM.NS has a market cap of 348.3B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while JBCHEPHARM.NS trades at ₹2,169.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas JBCHEPHARM.NS's P/E ratio is 48.74. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to JBCHEPHARM.NS's ROE of +0.19%. Regarding short-term risk, VENUSREM.NS is more volatile compared to JBCHEPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check JBCHEPHARM.NS's competition here
VENUSREM.NS vs EMCURE.NS Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, EMCURE.NS has a market cap of 333.1B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while EMCURE.NS trades at ₹1,756.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas EMCURE.NS's P/E ratio is 36.08. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to EMCURE.NS's ROE of +0.20%. Regarding short-term risk, VENUSREM.NS is more volatile compared to EMCURE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check EMCURE.NS's competition here
VENUSREM.NS vs WOCKPHARMA.NS Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, WOCKPHARMA.NS has a market cap of 312.1B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while WOCKPHARMA.NS trades at ₹1,920.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas WOCKPHARMA.NS's P/E ratio is 145.85. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to WOCKPHARMA.NS's ROE of +0.05%. Regarding short-term risk, VENUSREM.NS is less volatile compared to WOCKPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for VENUSREM.NS.Check WOCKPHARMA.NS's competition here
VENUSREM.NS vs WOCKPHARMA.BO Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, WOCKPHARMA.BO has a market cap of 312B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while WOCKPHARMA.BO trades at ₹1,920.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas WOCKPHARMA.BO's P/E ratio is 145.58. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to WOCKPHARMA.BO's ROE of +0.05%. Regarding short-term risk, VENUSREM.NS is less volatile compared to WOCKPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for VENUSREM.NS.Check WOCKPHARMA.BO's competition here
VENUSREM.NS vs PEL.NS Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, PEL.NS has a market cap of 254.9B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while PEL.NS trades at ₹1,124.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas PEL.NS's P/E ratio is 44.24. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to PEL.NS's ROE of +0.02%. Regarding short-term risk, VENUSREM.NS is less volatile compared to PEL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for VENUSREM.NS.Check PEL.NS's competition here
VENUSREM.NS vs PPLPHARMA.NS Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, PPLPHARMA.NS has a market cap of 220.9B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while PPLPHARMA.NS trades at ₹166.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas PPLPHARMA.NS's P/E ratio is -68.07. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to PPLPHARMA.NS's ROE of -0.04%. Regarding short-term risk, VENUSREM.NS is more volatile compared to PPLPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check PPLPHARMA.NS's competition here
VENUSREM.NS vs PPLPHARMA.BO Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, PPLPHARMA.BO has a market cap of 220.9B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while PPLPHARMA.BO trades at ₹166.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas PPLPHARMA.BO's P/E ratio is -68.06. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to PPLPHARMA.BO's ROE of -0.04%. Regarding short-term risk, VENUSREM.NS is more volatile compared to PPLPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check PPLPHARMA.BO's competition here
VENUSREM.NS vs NEULANDLAB.BO Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, NEULANDLAB.BO has a market cap of 215.7B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while NEULANDLAB.BO trades at ₹16,812.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas NEULANDLAB.BO's P/E ratio is 59.33. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to NEULANDLAB.BO's ROE of +0.22%. Regarding short-term risk, VENUSREM.NS is more volatile compared to NEULANDLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check NEULANDLAB.BO's competition here
VENUSREM.NS vs NEULANDLAB.NS Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, NEULANDLAB.NS has a market cap of 215.7B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while NEULANDLAB.NS trades at ₹16,811.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas NEULANDLAB.NS's P/E ratio is 59.35. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to NEULANDLAB.NS's ROE of +0.22%. Regarding short-term risk, VENUSREM.NS is more volatile compared to NEULANDLAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check NEULANDLAB.NS's competition here
VENUSREM.NS vs ASTRAZEN.NS Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, ASTRAZEN.NS has a market cap of 215B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while ASTRAZEN.NS trades at ₹8,600.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas ASTRAZEN.NS's P/E ratio is 114.21. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to ASTRAZEN.NS's ROE of +0.23%. Regarding short-term risk, VENUSREM.NS is more volatile compared to ASTRAZEN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check ASTRAZEN.NS's competition here
VENUSREM.NS vs ASTRAZEN.BO Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, ASTRAZEN.BO has a market cap of 215B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while ASTRAZEN.BO trades at ₹8,598.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas ASTRAZEN.BO's P/E ratio is 114.30. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to ASTRAZEN.BO's ROE of +0.23%. Regarding short-term risk, VENUSREM.NS is more volatile compared to ASTRAZEN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check ASTRAZEN.BO's competition here
VENUSREM.NS vs GRANULES.NS Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, GRANULES.NS has a market cap of 195.7B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while GRANULES.NS trades at ₹789.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas GRANULES.NS's P/E ratio is 32.30. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to GRANULES.NS's ROE of +0.14%. Regarding short-term risk, VENUSREM.NS is more volatile compared to GRANULES.NS. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check GRANULES.NS's competition here
VENUSREM.NS vs GRANULES.BO Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, GRANULES.BO has a market cap of 191.6B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while GRANULES.BO trades at ₹789.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas GRANULES.BO's P/E ratio is 35.11. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to GRANULES.BO's ROE of +0.14%. Regarding short-term risk, VENUSREM.NS is more volatile compared to GRANULES.BO. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check GRANULES.BO's competition here
VENUSREM.NS vs ERIS.NS Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, ERIS.NS has a market cap of 189.2B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while ERIS.NS trades at ₹1,365.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas ERIS.NS's P/E ratio is 30.16. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to ERIS.NS's ROE of +0.19%. Regarding short-term risk, VENUSREM.NS is more volatile compared to ERIS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check ERIS.NS's competition here
VENUSREM.NS vs ERIS.BO Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, ERIS.BO has a market cap of 188.6B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while ERIS.BO trades at ₹1,361.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas ERIS.BO's P/E ratio is 30.07. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to ERIS.BO's ROE of +0.19%. Regarding short-term risk, VENUSREM.NS is more volatile compared to ERIS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check ERIS.BO's competition here
VENUSREM.NS vs COHANCE.NS Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, COHANCE.NS has a market cap of 164.9B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while COHANCE.NS trades at ₹431.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas COHANCE.NS's P/E ratio is 92.31. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to COHANCE.NS's ROE of +0.06%. Regarding short-term risk, VENUSREM.NS is less volatile compared to COHANCE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for VENUSREM.NS.Check COHANCE.NS's competition here
VENUSREM.NS vs COHANCE.BO Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, COHANCE.BO has a market cap of 164.9B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while COHANCE.BO trades at ₹430.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas COHANCE.BO's P/E ratio is 92.28. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to COHANCE.BO's ROE of +0.06%. Regarding short-term risk, VENUSREM.NS is less volatile compared to COHANCE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for VENUSREM.NS.Check COHANCE.BO's competition here
VENUSREM.NS vs NATCOPHARM.BO Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, NATCOPHARM.BO has a market cap of 160.1B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while NATCOPHARM.BO trades at ₹893.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas NATCOPHARM.BO's P/E ratio is 10.40. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to NATCOPHARM.BO's ROE of +0.17%. Regarding short-term risk, VENUSREM.NS is more volatile compared to NATCOPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check NATCOPHARM.BO's competition here
VENUSREM.NS vs NATCOPHARM.NS Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, NATCOPHARM.NS has a market cap of 160B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while NATCOPHARM.NS trades at ₹893.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas NATCOPHARM.NS's P/E ratio is 11.28. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to NATCOPHARM.NS's ROE of +0.17%. Regarding short-term risk, VENUSREM.NS is more volatile compared to NATCOPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check NATCOPHARM.NS's competition here
VENUSREM.NS vs CAPLIPOINT.NS Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, CAPLIPOINT.NS has a market cap of 154.5B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while CAPLIPOINT.NS trades at ₹2,033.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas CAPLIPOINT.NS's P/E ratio is 24.20. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to CAPLIPOINT.NS's ROE of +0.21%. Regarding short-term risk, VENUSREM.NS is more volatile compared to CAPLIPOINT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check CAPLIPOINT.NS's competition here
VENUSREM.NS vs CAPLIPOINT.BO Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, CAPLIPOINT.BO has a market cap of 154.4B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while CAPLIPOINT.BO trades at ₹2,031.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas CAPLIPOINT.BO's P/E ratio is 24.18. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to CAPLIPOINT.BO's ROE of +0.21%. Regarding short-term risk, VENUSREM.NS is more volatile compared to CAPLIPOINT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check CAPLIPOINT.BO's competition here
VENUSREM.NS vs JUBLPHARMA.NS Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, JUBLPHARMA.NS has a market cap of 154.2B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while JUBLPHARMA.NS trades at ₹973.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas JUBLPHARMA.NS's P/E ratio is 38.88. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to JUBLPHARMA.NS's ROE of +0.06%. Regarding short-term risk, VENUSREM.NS is more volatile compared to JUBLPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check JUBLPHARMA.NS's competition here
VENUSREM.NS vs JUBLPHARMA.BO Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, JUBLPHARMA.BO has a market cap of 154.2B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while JUBLPHARMA.BO trades at ₹973.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas JUBLPHARMA.BO's P/E ratio is 38.83. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to JUBLPHARMA.BO's ROE of +0.06%. Regarding short-term risk, VENUSREM.NS is more volatile compared to JUBLPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check JUBLPHARMA.BO's competition here
VENUSREM.NS vs APLLTD.NS Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, APLLTD.NS has a market cap of 145.1B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while APLLTD.NS trades at ₹738.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas APLLTD.NS's P/E ratio is 21.53. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to APLLTD.NS's ROE of +0.13%. Regarding short-term risk, VENUSREM.NS is more volatile compared to APLLTD.NS. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check APLLTD.NS's competition here
VENUSREM.NS vs APLLTD.BO Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, APLLTD.BO has a market cap of 144.9B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while APLLTD.BO trades at ₹736.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas APLLTD.BO's P/E ratio is 21.45. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to APLLTD.BO's ROE of +0.13%. Regarding short-term risk, VENUSREM.NS is more volatile compared to APLLTD.BO. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check APLLTD.BO's competition here
VENUSREM.NS vs GLS.NS Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, GLS.NS has a market cap of 133.1B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while GLS.NS trades at ₹1,086.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas GLS.NS's P/E ratio is 31.50. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to GLS.NS's ROE of +0.21%. Regarding short-term risk, VENUSREM.NS is more volatile compared to GLS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check GLS.NS's competition here
VENUSREM.NS vs GLS.BO Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, GLS.BO has a market cap of 133B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while GLS.BO trades at ₹1,085.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas GLS.BO's P/E ratio is 30.23. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to GLS.BO's ROE of +0.09%. Regarding short-term risk, VENUSREM.NS is more volatile compared to GLS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check GLS.BO's competition here
VENUSREM.NS vs ALIVUS.NS Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, ALIVUS.NS has a market cap of 126.7B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while ALIVUS.NS trades at ₹1,032.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas ALIVUS.NS's P/E ratio is 22.50. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to ALIVUS.NS's ROE of +0.18%. Regarding short-term risk, VENUSREM.NS is more volatile compared to ALIVUS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check ALIVUS.NS's competition here
VENUSREM.NS vs ALIVUS.BO Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, ALIVUS.BO has a market cap of 126.5B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while ALIVUS.BO trades at ₹1,030.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas ALIVUS.BO's P/E ratio is 22.47. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to ALIVUS.BO's ROE of +0.21%. Regarding short-term risk, VENUSREM.NS is more volatile compared to ALIVUS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check ALIVUS.BO's competition here
VENUSREM.NS vs VIYASH.NS Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, VIYASH.NS has a market cap of 111.4B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while VIYASH.NS trades at ₹255.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas VIYASH.NS's P/E ratio is 63.50. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to VIYASH.NS's ROE of +0.09%. Regarding short-term risk, VENUSREM.NS is more volatile compared to VIYASH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check VIYASH.NS's competition here
VENUSREM.NS vs CAPPL.BO Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, CAPPL.BO has a market cap of 109.4B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while CAPPL.BO trades at ₹1,446.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas CAPPL.BO's P/E ratio is 50.30. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to CAPPL.BO's ROE of +0.10%. Regarding short-term risk, VENUSREM.NS is less volatile compared to CAPPL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for VENUSREM.NS.Check CAPPL.BO's competition here
VENUSREM.NS vs SHILPAMED.NS Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, SHILPAMED.NS has a market cap of 105.2B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while SHILPAMED.NS trades at ₹538.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas SHILPAMED.NS's P/E ratio is 43.18. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to SHILPAMED.NS's ROE of +0.10%. Regarding short-term risk, VENUSREM.NS is more volatile compared to SHILPAMED.NS. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check SHILPAMED.NS's competition here
VENUSREM.NS vs PGHL.NS Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, PGHL.NS has a market cap of 102.9B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while PGHL.NS trades at ₹6,200.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas PGHL.NS's P/E ratio is 31.44. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to PGHL.NS's ROE of +0.59%. Regarding short-term risk, VENUSREM.NS is more volatile compared to PGHL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check PGHL.NS's competition here
VENUSREM.NS vs PGHL.BO Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, PGHL.BO has a market cap of 102.5B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while PGHL.BO trades at ₹6,172.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas PGHL.BO's P/E ratio is 31.36. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to PGHL.BO's ROE of +0.59%. Regarding short-term risk, VENUSREM.NS is more volatile compared to PGHL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check PGHL.BO's competition here
VENUSREM.NS vs STAR.NS Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, STAR.NS has a market cap of 96.3B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while STAR.NS trades at ₹1,044.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas STAR.NS's P/E ratio is 17.32. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to STAR.NS's ROE of +0.20%. Regarding short-term risk, VENUSREM.NS is more volatile compared to STAR.NS. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check STAR.NS's competition here
VENUSREM.NS vs STAR.BO Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, STAR.BO has a market cap of 96.1B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while STAR.BO trades at ₹1,042.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas STAR.BO's P/E ratio is 17.29. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to STAR.BO's ROE of +0.20%. Regarding short-term risk, VENUSREM.NS is more volatile compared to STAR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check STAR.BO's competition here
VENUSREM.NS vs SUDEEPPHRM.NS Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, SUDEEPPHRM.NS has a market cap of 85.2B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while SUDEEPPHRM.NS trades at ₹754.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas SUDEEPPHRM.NS's P/E ratio is 50.60. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to SUDEEPPHRM.NS's ROE of N/A. Regarding short-term risk, VENUSREM.NS is less volatile compared to SUDEEPPHRM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for VENUSREM.NS.Check SUDEEPPHRM.NS's competition here
VENUSREM.NS vs AKUMS.NS Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, AKUMS.NS has a market cap of 84.8B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while AKUMS.NS trades at ₹553.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas AKUMS.NS's P/E ratio is 33.20. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to AKUMS.NS's ROE of +0.08%. Regarding short-term risk, VENUSREM.NS is more volatile compared to AKUMS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check AKUMS.NS's competition here
VENUSREM.NS vs SPARC.NS Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, SPARC.NS has a market cap of 69.1B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while SPARC.NS trades at ₹212.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas SPARC.NS's P/E ratio is 4.45. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to SPARC.NS's ROE of +11.09%. Regarding short-term risk, VENUSREM.NS is less volatile compared to SPARC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for VENUSREM.NS.Check SPARC.NS's competition here
VENUSREM.NS vs SPARC.BO Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, SPARC.BO has a market cap of 68.9B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while SPARC.BO trades at ₹212.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas SPARC.BO's P/E ratio is 4.44. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to SPARC.BO's ROE of +11.09%. Regarding short-term risk, VENUSREM.NS is less volatile compared to SPARC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for VENUSREM.NS.Check SPARC.BO's competition here
VENUSREM.NS vs FDC.NS Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, FDC.NS has a market cap of 62B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while FDC.NS trades at ₹381.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas FDC.NS's P/E ratio is 22.05. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to FDC.NS's ROE of +0.12%. Regarding short-term risk, VENUSREM.NS is less volatile compared to FDC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for VENUSREM.NS.Check FDC.NS's competition here
VENUSREM.NS vs FDC.BO Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, FDC.BO has a market cap of 62B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while FDC.BO trades at ₹380.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas FDC.BO's P/E ratio is 22.02. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to FDC.BO's ROE of +0.12%. Regarding short-term risk, VENUSREM.NS is less volatile compared to FDC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for VENUSREM.NS.Check FDC.BO's competition here
VENUSREM.NS vs AARTIPHARM.BO Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, AARTIPHARM.BO has a market cap of 57.1B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while AARTIPHARM.BO trades at ₹629.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas AARTIPHARM.BO's P/E ratio is 32.66. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to AARTIPHARM.BO's ROE of +0.09%. Regarding short-term risk, VENUSREM.NS is more volatile compared to AARTIPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check AARTIPHARM.BO's competition here
VENUSREM.NS vs AARTIPHARM.NS Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, AARTIPHARM.NS has a market cap of 57B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while AARTIPHARM.NS trades at ₹628.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas AARTIPHARM.NS's P/E ratio is 32.64. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to AARTIPHARM.NS's ROE of +0.09%. Regarding short-term risk, VENUSREM.NS is less volatile compared to AARTIPHARM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for VENUSREM.NS.Check AARTIPHARM.NS's competition here
VENUSREM.NS vs SUVEN.BO Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, SUVEN.BO has a market cap of 55B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while SUVEN.BO trades at ₹237.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas SUVEN.BO's P/E ratio is -19.26. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to SUVEN.BO's ROE of -1.01%. Regarding short-term risk, VENUSREM.NS is less volatile compared to SUVEN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for VENUSREM.NS.Check SUVEN.BO's competition here
VENUSREM.NS vs SUVEN.NS Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, SUVEN.NS has a market cap of 53.2B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while SUVEN.NS trades at ₹237.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas SUVEN.NS's P/E ratio is -19.55. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to SUVEN.NS's ROE of -1.01%. Regarding short-term risk, VENUSREM.NS is less volatile compared to SUVEN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for VENUSREM.NS.Check SUVEN.NS's competition here
VENUSREM.NS vs SHILPAMED.BO Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, SHILPAMED.BO has a market cap of 52.5B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while SHILPAMED.BO trades at ₹536.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas SHILPAMED.BO's P/E ratio is 43.22. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to SHILPAMED.BO's ROE of +0.10%. Regarding short-term risk, VENUSREM.NS is more volatile compared to SHILPAMED.BO. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check SHILPAMED.BO's competition here
VENUSREM.NS vs SEQUENT.BO Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, SEQUENT.BO has a market cap of 50.6B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while SEQUENT.BO trades at ₹202.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas SEQUENT.BO's P/E ratio is 123.41. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to SEQUENT.BO's ROE of +0.06%. Regarding short-term risk, VENUSREM.NS is more volatile compared to SEQUENT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check SEQUENT.BO's competition here
VENUSREM.NS vs SEQUENT.NS Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, SEQUENT.NS has a market cap of 50.6B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while SEQUENT.NS trades at ₹202.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas SEQUENT.NS's P/E ratio is 124.17. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to SEQUENT.NS's ROE of +0.06%. Regarding short-term risk, VENUSREM.NS is more volatile compared to SEQUENT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check SEQUENT.NS's competition here
VENUSREM.NS vs INNOVACAP.NS Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, INNOVACAP.NS has a market cap of 49.6B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while INNOVACAP.NS trades at ₹867.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas INNOVACAP.NS's P/E ratio is 35.26. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to INNOVACAP.NS's ROE of +0.14%. Regarding short-term risk, VENUSREM.NS is more volatile compared to INNOVACAP.NS. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check INNOVACAP.NS's competition here
VENUSREM.NS vs BLISSGVS.NS Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, BLISSGVS.NS has a market cap of 46.4B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while BLISSGVS.NS trades at ₹438.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas BLISSGVS.NS's P/E ratio is 36.53. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to BLISSGVS.NS's ROE of +0.12%. Regarding short-term risk, VENUSREM.NS is less volatile compared to BLISSGVS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for VENUSREM.NS.Check BLISSGVS.NS's competition here
VENUSREM.NS vs BLISSGVS.BO Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, BLISSGVS.BO has a market cap of 46.3B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while BLISSGVS.BO trades at ₹438.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas BLISSGVS.BO's P/E ratio is 36.50. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to BLISSGVS.BO's ROE of +0.12%. Regarding short-term risk, VENUSREM.NS is less volatile compared to BLISSGVS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for VENUSREM.NS.Check BLISSGVS.BO's competition here
VENUSREM.NS vs GUJTHEM.NS Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, GUJTHEM.NS has a market cap of 45B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while GUJTHEM.NS trades at ₹413.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas GUJTHEM.NS's P/E ratio is 96.09. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to GUJTHEM.NS's ROE of +0.17%. Regarding short-term risk, VENUSREM.NS is more volatile compared to GUJTHEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check GUJTHEM.NS's competition here
VENUSREM.NS vs ORCHPHARMA.NS Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, ORCHPHARMA.NS has a market cap of 42.8B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while ORCHPHARMA.NS trades at ₹844.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas ORCHPHARMA.NS's P/E ratio is 208.97. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to ORCHPHARMA.NS's ROE of +0.02%. Regarding short-term risk, VENUSREM.NS is more volatile compared to ORCHPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check ORCHPHARMA.NS's competition here
VENUSREM.NS vs ORCHPHARMA.BO Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, ORCHPHARMA.BO has a market cap of 42.7B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while ORCHPHARMA.BO trades at ₹841.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas ORCHPHARMA.BO's P/E ratio is 205.72. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to ORCHPHARMA.BO's ROE of +0.02%. Regarding short-term risk, VENUSREM.NS is more volatile compared to ORCHPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check ORCHPHARMA.BO's competition here
VENUSREM.NS vs IOLCP.NS Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, IOLCP.NS has a market cap of 38.7B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while IOLCP.NS trades at ₹131.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas IOLCP.NS's P/E ratio is 28.14. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to IOLCP.NS's ROE of +0.08%. Regarding short-term risk, VENUSREM.NS is less volatile compared to IOLCP.NS. This indicates potentially lower risk in terms of short-term price fluctuations for VENUSREM.NS.Check IOLCP.NS's competition here
VENUSREM.NS vs IOLCP.BO Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, IOLCP.BO has a market cap of 38.6B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while IOLCP.BO trades at ₹131.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas IOLCP.BO's P/E ratio is 28.05. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to IOLCP.BO's ROE of +0.08%. Regarding short-term risk, VENUSREM.NS is less volatile compared to IOLCP.BO. This indicates potentially lower risk in terms of short-term price fluctuations for VENUSREM.NS.Check IOLCP.BO's competition here
VENUSREM.NS vs GUFICBIO.NS Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, GUFICBIO.NS has a market cap of 37.1B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while GUFICBIO.NS trades at ₹369.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas GUFICBIO.NS's P/E ratio is 57.71. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to GUFICBIO.NS's ROE of +0.10%. Regarding short-term risk, VENUSREM.NS is less volatile compared to GUFICBIO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for VENUSREM.NS.Check GUFICBIO.NS's competition here
VENUSREM.NS vs GUFICBIO.BO Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, GUFICBIO.BO has a market cap of 37.1B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while GUFICBIO.BO trades at ₹369.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas GUFICBIO.BO's P/E ratio is 57.83. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to GUFICBIO.BO's ROE of +0.10%. Regarding short-term risk, VENUSREM.NS is less volatile compared to GUFICBIO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for VENUSREM.NS.Check GUFICBIO.BO's competition here
VENUSREM.NS vs RPGLIFE.BO Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, RPGLIFE.BO has a market cap of 35.8B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while RPGLIFE.BO trades at ₹2,164.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas RPGLIFE.BO's P/E ratio is 31.06. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to RPGLIFE.BO's ROE of +0.21%. Regarding short-term risk, VENUSREM.NS is more volatile compared to RPGLIFE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check RPGLIFE.BO's competition here
VENUSREM.NS vs RPGLIFE.NS Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, RPGLIFE.NS has a market cap of 35.8B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while RPGLIFE.NS trades at ₹2,161.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas RPGLIFE.NS's P/E ratio is 31.00. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to RPGLIFE.NS's ROE of +0.21%. Regarding short-term risk, VENUSREM.NS is more volatile compared to RPGLIFE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check RPGLIFE.NS's competition here
VENUSREM.NS vs AARTIDRUGS.BO Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, AARTIDRUGS.BO has a market cap of 34.4B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while AARTIDRUGS.BO trades at ₹377.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas AARTIDRUGS.BO's P/E ratio is 17.67. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to AARTIDRUGS.BO's ROE of +0.14%. Regarding short-term risk, VENUSREM.NS is more volatile compared to AARTIDRUGS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check AARTIDRUGS.BO's competition here
VENUSREM.NS vs AARTIDRUGS.NS Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, AARTIDRUGS.NS has a market cap of 34.4B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while AARTIDRUGS.NS trades at ₹376.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas AARTIDRUGS.NS's P/E ratio is 17.66. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to AARTIDRUGS.NS's ROE of +0.14%. Regarding short-term risk, VENUSREM.NS is more volatile compared to AARTIDRUGS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check AARTIDRUGS.NS's competition here
VENUSREM.NS vs NOVARTIND.NS Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, NOVARTIND.NS has a market cap of 34.3B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while NOVARTIND.NS trades at ₹1,391.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas NOVARTIND.NS's P/E ratio is 36.89. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to NOVARTIND.NS's ROE of +0.12%. Regarding short-term risk, VENUSREM.NS is more volatile compared to NOVARTIND.NS. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check NOVARTIND.NS's competition here
VENUSREM.NS vs NOVARTIND.BO Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, NOVARTIND.BO has a market cap of 34.3B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while NOVARTIND.BO trades at ₹1,388.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas NOVARTIND.BO's P/E ratio is 36.74. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to NOVARTIND.BO's ROE of +0.12%. Regarding short-term risk, VENUSREM.NS is less volatile compared to NOVARTIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for VENUSREM.NS.Check NOVARTIND.BO's competition here
VENUSREM.NS vs SOLARA.BO Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, SOLARA.BO has a market cap of 25.8B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while SOLARA.BO trades at ₹536.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas SOLARA.BO's P/E ratio is -321.17. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to SOLARA.BO's ROE of -0.01%. Regarding short-term risk, VENUSREM.NS is more volatile compared to SOLARA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check SOLARA.BO's competition here
VENUSREM.NS vs SOLARA.NS Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, SOLARA.NS has a market cap of 25.8B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while SOLARA.NS trades at ₹534.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas SOLARA.NS's P/E ratio is -320.27. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to SOLARA.NS's ROE of -0.01%. Regarding short-term risk, VENUSREM.NS is more volatile compared to SOLARA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check SOLARA.NS's competition here
VENUSREM.NS vs UNICHEMLAB.NS Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, UNICHEMLAB.NS has a market cap of 25.6B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while UNICHEMLAB.NS trades at ₹363.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas UNICHEMLAB.NS's P/E ratio is 10.13. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to UNICHEMLAB.NS's ROE of +0.10%. Regarding short-term risk, VENUSREM.NS is more volatile compared to UNICHEMLAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check UNICHEMLAB.NS's competition here
VENUSREM.NS vs UNICHEMLAB.BO Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, UNICHEMLAB.BO has a market cap of 25.5B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while UNICHEMLAB.BO trades at ₹362.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas UNICHEMLAB.BO's P/E ratio is 10.12. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to UNICHEMLAB.BO's ROE of +0.10%. Regarding short-term risk, VENUSREM.NS is more volatile compared to UNICHEMLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for VENUSREM.NS.Check UNICHEMLAB.BO's competition here
VENUSREM.NS vs MOREPENLAB.BO Comparison June 2026
VENUSREM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VENUSREM.NS stands at 21.8B. In comparison, MOREPENLAB.BO has a market cap of 24B. Regarding current trading prices, VENUSREM.NS is priced at ₹1,633.50, while MOREPENLAB.BO trades at ₹43.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VENUSREM.NS currently has a P/E ratio of 21.24, whereas MOREPENLAB.BO's P/E ratio is 24.46. In terms of profitability, VENUSREM.NS's ROE is +0.17%, compared to MOREPENLAB.BO's ROE of +0.08%. Regarding short-term risk, VENUSREM.NS is less volatile compared to MOREPENLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for VENUSREM.NS.Check MOREPENLAB.BO's competition here